RIPK1 and Alzheimer disease: RIPK1 and MLKL levels are elevated in human AD brains and correlate with Braak stage. Necroptosis is activated in AD neurons, indicated by the increase in MLKL phosphorylation and RIPK1/MLKL interactions. Pharmacological inhibition of necroptosis reduces neuronal loss and cognitive decline in AD mice.